Denali Therapeutics (DNLI) Expected to Announce Earnings on Thursday

Denali Therapeutics (NASDAQ:DNLI) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.75) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Denali Therapeutics Price Performance

DNLI opened at $19.23 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79. The stock’s 50 day simple moving average is $18.54 and its 200 day simple moving average is $16.76. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -6.61 and a beta of 1.02. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares in the company, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the sale, the insider directly owned 282,828 shares in the company, valued at approximately $4,666,662. This represents a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 12.50% of the stock is currently owned by company insiders.

Institutional Trading of Denali Therapeutics

Large investors have recently made changes to their positions in the stock. Headlands Technologies LLC bought a new position in shares of Denali Therapeutics in the second quarter worth about $26,000. State of Wyoming bought a new stake in Denali Therapeutics during the 2nd quarter worth approximately $29,000. Johnson Financial Group Inc. purchased a new position in Denali Therapeutics during the third quarter valued at approximately $29,000. Aster Capital Management DIFC Ltd bought a new position in shares of Denali Therapeutics in the fourth quarter worth approximately $57,000. Finally, Quarry LP purchased a new stake in shares of Denali Therapeutics in the third quarter worth $64,000. 92.92% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DNLI. Morgan Stanley reissued an “overweight” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. Wedbush reduced their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Stifel Nicolaus set a $37.00 price target on Denali Therapeutics in a research note on Monday, November 17th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Denali Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $32.27.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.